1461086477-966e12d9-4083-4442-badc-6b53b29d5904

1. Modified carbon nanotube comprising a carbon nanotube core covalently bound to a polymer shell surrounding the carbon nanotube core, wherein said covalent bond consists of a bond between a carbon atom on the carbon nanotube core and a carbon atom on the polymer shell, and wherein the polymer shell comprises a homopolymer of 4-vinylaniline or a copolymer of 4-vinylaniline and one or more other types of multifunctional monomers having one or more functional groups compatible with or able to covalently connect to another polymer.
2. The modified carbon nanotube according to claim 1, wherein the carbon nanotube core comprises single-walled or multi-walled carbon nanotube.
3. The modified carbon nanotube according to claim 1, wherein the functional groups comprise amino, hydroxyl, sulfonato, oxycarbonyl, halo, acetyl, epoxy, amido, diazo, anhydride or carboxyl functional groups or mixtures thereof.
4. The modified carbon nanotube according to claim 1, wherein the multifunctional monomer comprises a vinylaniline, vinyl alcohol, a vinyl alkyl alcohol, a vinyl phenol, a styrene derivative, vinyl ester, vinyl chloride, vinyl acetate, methacrylic acid, a methacrylate, acrylic acid, an acrylate, acrylamide, acrylonitrile or any mixture thereof.
5. The modified carbon nanotube according to claim 1, wherein the multifunctional monomer comprises vinyl alcohol, 4-penten-1-ol, 2-methoxy-4-vinylphenol, styrene sodium sulfonate, vinyl ester, vinyl chloride, vinyl acetate, methacrylic acid, glycidyl methacrylate, methyl methacrylate, acrylic acid, methyl acrylate, acrylamide, acrylonitrile or mixtures thereof.
6. The modified carbon nanotube according to claim 1 wherein the multifunctional monomer comprises glycidyl methacrylate.
7. The modified carbon nanotube according to claim 1, further comprising a secondary compatibilizer.
8. The modified carbon nanotube according to claim 7, wherein the secondary compatibilizer comprises polyethylene-graft-glycidyl methacrylate, polypropylene-graft-glycidyl methacrylate, polyethylene-graft-maleic anhydride, polypropylene-graft-maleic anhydride or any mixture thereof.
9. The modified carbon nanotube according to claim 1, wherein the polymer shell has a uniform thickness in a range of 10-400 nm.
10. The modified carbon nanotube according to claim 1, wherein the carbon nanotube core has a substantially unidirectional orientation along the longitudinal axis of CNT within the polymer shell.
11. The modified carbon nanotube according to claim 1 for use as a reinforcing filler in a polymer matrix.
12. A polymeric nanocomposite comprising modified carbon nanotubes as defined in claim 1.
13. The polymeric nanocomposite according to claim 12, wherein the modified carbon nanotubes are mixed with another polymer.
14. The polymeric nanocomposite according to claim 13, wherein the modified carbon nanotubes are homogeneously distributed in a matrix of the other polymer.
15. The polymeric nanocomposite according to claim 13, wherein the other polymer comprises a polyethylene, a polypropylene, a polystyrene, a polybutadiene, a poly(acetylene), a poly(pyrrole), a poly(thiophene), a polyaniline, a polythiophene, a poly(p-phenylene sulfide), a poly(p-phenylene vinylene), a polycarbonate, polymethylmethacrylate, a polyisoprene, a single component epoxy resin, an epoxy resin system, an epoxy vinyl ester resin or any mixture thereof.
16. A process of producing modified carbon nanotube, the process comprising: reacting neutral carbon nanotube with 4-vinylaniline in an organic solvent through a diazonium reaction in presence of one or more types of multifunctional monomers carrying a vinyl moiety and one or more functional groups for compatibilization with or connection to another polymer, the reaction conducted at least in part at a temperature of from 25\xb0 C. to 120\xb0 C. without isolation of intermediates and without addition of any extra initiator or catalyst to form a polymer shell in situ around the carbon nanotube, the polymer shell covalently bound to carbon nanotube sidewall through C\u2014C bonds and wherein the polymer shell comprises a homopolymer of 4-vinylaniline or a copolymer of 4-vinylaniline and one or more other types of multifunctional monomers having one or more functional groups compatible with or able to covalently connect to another polymer.
17. The process according to claim 16, wherein the diazonium reaction is effected with a diazotization agent comprising isoamyl nitrite.
18. The process according to claim 16, wherein the functional groups comprise amino, hydroxyl, sulfonato, oxycarbony, halo, acetyl, epoxy, amido, diazo, anhydride or carboxyl functional groups or mixtures thereof.
19. The process according to claim 16, wherein the multifunctional monomers comprise a vinylaniline, vinyl alcohol, a vinyl alkyl alcohol, a vinyl phenol, a styrene derivative, vinyl ester, vinyl chloride, vinyl acetate, methacrylic acid, a methacrylate, acrylic acid, an acrylate, acrylamide, acrylonitrile or any mixture thereof.
20. The process according to claim 16, wherein the multifunctional monomers comprise vinyl alcohol, 4-penten-1-ol, 2-methoxy-4-vinylphenol, styrene sodium sulfonate, vinyl ester, vinyl chloride, vinyl acetate, methacrylic acid, glycidyl methacrylate, methyl methacrylate, acrylic acid, methyl acrylate, acrylamide, acrylonitrile or mixtures thereof.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A non-transitory machine-readable medium having executable instructions to cause one or more processing units to perform a method comprising:
receiving a first group of messages and a second group of messages, wherein each of the messages in the first and second group of messages includes a plurality of message addresses;
selecting a related message from the second group of messages that is related to each message in the first group of messages, wherein the selecting is based on an affinity group of message addresses, the affinity group includes message addresses representing entities that communicate with each other for a particular common purpose, the affinity group is determined using the plurality of message addresses contained in the first and second groups of messages, and the selecting the related message includes,
computing the affinity group using a probability that the one of the message addresses appears in a message in the first and second group of messages with another message address, and
computing a message signature with the affinity group; and
generating data to present the related message.
2. The non-transitory machine-readable medium of claim 1, wherein the affinity group is a group of message addresses that are related to each other.
3. The non-transitory machine-readable medium of claim 1, wherein a message is of a type selected from the group consisting of email, Short Message Service, Multimedia Message Service, Enhanced Message Service, TWITTER, FACEBOOK, telephone message log, and instant messaging.
4. The non-transitory machine-readable medium of claim 3, wherein the first and second group of messages includes a plurality of message types.
5. The non-transitory machine-readable medium of claim 1, wherein the selecting comprises:
computing the message signature for each message in the first and second group of messages.
6. The non-transitory machine-readable medium of claim 5, wherein the message signature for a message is a distance vector between the affinity group and a plurality of addresses associated with that message.
7. The non-transitory machine-readable medium of claim 5, wherein the selecting further comprises:
computing a similarity value between the message signature of a message in the first group and the message signature of a message in the second group to result in a plurality of similarity values; and
determining the related message from the plurality of similarity values.
8. The non-transitory machine-readable medium of claim 1, wherein the entities communicate above a minimum frequency regarding the particular common purpose.
9. A non-transitory machine-readable medium having executable instructions to cause one or more processing units to perform a method comprising:
receiving a first group of messages and a second group of messages, wherein each of the messages in the first and second group of messages includes a plurality of message addresses;
selecting a related message from the second group of messages that is related to each message in the first group of messages, wherein the selecting is based on an affinity group of message addresses, the affinity group includes a message address that occurs in at least one of the messages in the second group, the affinity group is determined using the plurality of message addresses contained in the first and second groups of messages, and the selecting the related message includes,
computing the affinity group using a probability that the one of the message addresses appears in a message in the first and second group of messages with another message address, and
computing a message signature with the affinity group; and
generating data to present the related message.
10. The non-transitory machine-readable medium of claim 9, wherein the affinity group is a group of message addresses that are related to each other.
11. The non-transitory machine-readable medium of claim 9, wherein the first and second group of messages includes a plurality of message types.
12. The non-transitory machine-readable medium of claim 9, wherein the selecting comprises:
computing the message signature for each message in the first and second group of messages.
13. The non-transitory machine-readable medium of claim 12, wherein the message signature for a message is a distance vector between the affinity group and a plurality of addresses associated with that message.
14. The non-transitory machine-readable medium of claim 12, wherein the selecting further comprises:
computing a similarity value between the message signature of a message in the first group and the message signature of a message in the second group to result in a plurality of similarity values; and
determining the related message from the plurality of similarity values.
15. An apparatus comprising: a processor;
a memory coupled to the processor though a bus; and
a process executed from the memory by the processor that causes the processor to receive a first group of messages and a second group of messages, wherein each of the messages in the first and second group of messages includes a plurality of message addresses,
select a related message from the second group of messages that is related to each message in the first group of messages, wherein the selecting is based on an affinity group of message addresses, the affinity group includes a message address that occurs in at least one of the messages in the second group and the affinity group is determined using the plurality of message addresses contained in the first and second groups of messages, and the process further causes the processor to select the related message by,
computing the affinity group using a probability that the one of the message addresses appears in a message in the first and second group of messages with another message address, and computing a message signature with the affinity groups, and
generate data to present the related message.
16. The apparatus of claim 15, wherein the affinity group is a group of message addresses that are related to each other.
17. The apparatus of claim 15, wherein the first and second group of messages includes a plurality of message types.
18. The apparatus of claim 15, wherein the process further causes the processor to select the related message by:
computing message signature for each message in the first and second group of messages.
19. The apparatus of claim 18, wherein the message signature for a message is a distance vector between the affinity group and a plurality of addresses associated with that message.
20. The apparatus of claim 15, wherein the process further causes the processor to select the related message by:
computing a similarity value between the message signature of a message in the first group and the message signature of a message in the second group to result in a plurality of similarity values; and
determining the related message from the plurality of similarity values.

1461086466-033aa360-6d9f-49b5-9003-248fdc45ba33

1-8. (canceled)
9. A cryogenic fluid tank, comprising an outer envelope and an inner envelope, the interspace between the envelopes being occupied by a multilayer insulating structure, wherein the inner envelope is supported on a pivot point (A) formed by a support structure secured to the outer envelope and extending inside the latter, the pivot point being situated above the center of gravity (G) of the inner envelope.
10. The tank of claim 9, wherein the support structure extends inside a hollow volume of the inner envelope.
11. The tank of claim 10, wherein it has lines for the transfer of fluids andor electrical signals communicating with the inside of the inner envelope and extending outwards into the support structure.
12. The tank of claim 9, wherein the inner envelope has a generally cylindrical configuration with a longitudinal axis.
13. The tank of claim 12, wherein the support structure is orthogonal to the longitudinal axis.
14. The tank of claim 10, wherein the hollow volume is formed by a bell-shaped structure extending transversely centrally inside the inner envelope.
15. The tank of claim 9, wherein the pivot point is formed by a ball joint positioned between the walls of the hollow volume and the support structure.
16. A use of the tank of claim 9 in a motor vehicle.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of synthesizing stereochemically defined iminocyclitol comprising
replacing an intraring oxygen in a cyclic sugar by an intraring imine to form an iminocyclitol, wherein said iminocyclitol has a defined stereochemical configuration different from a stereochemical configuration of the cyclic sugar.
2. The method of claim 1, wherein said replacing an intraring oxygen comprises reacting the cyclic sugar with a reagent comprising NH3.
3. The method of claim 1, wherein the cyclic sugar is an aldopentose in a 4-deoxy 1,4 furanose form, an aldohexose in a 4-deoxy 1,4 furanose form or an aldohexose in a 2,5-dideoxy pyranose form and wherein the cyclic sugar is substituted at the C1 position by R1, wherein R1 is an alkyl group comprising from 1 to 20 carbon atoms.
4. The method of claim 3, further comprising reacting a protected lactone compound with a Grignard reagent R1MgX to form the cyclic sugar, wherein a stereochemical configuration of the protected lactone compound is the same as the stereochemical configuration of the cyclic sugar.
5. The method of claim 4, further comprising protecting hydroxyl groups of an unprotected lactone compound to form the protected lactone compound, wherein a stereochemical configuration of the unprotected lactone compound is the same as the stereochemical configuration of the protected lactone compound.
6. The method of claim 5, wherein the unprotected lactone compound is an aldopentose or an aldohexose in a 4-deoxy 1,4 furanose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C5 atom of the unprotected lactone compound with methanesulfonate, tosylate or triflate protective group.
7. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 4-deoxy 1,4 furanose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C6 atom of the unprotected lactone compound with a trityl or t-butyldimethylsiloxy group.
8. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 2,5-dideoxy pyranose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C6 atom of the unprotected lactone compound with a methanesulfonate protective group.
9. The method of claim 5, wherein the unprotected lactone compound an aldopentose or an aldohexose in a 4-deoxy 1,4 furanose and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C2 atom and a hydroxyl group on the C3 atom by an isopropyldene.
10. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 2,5-dideoxy pyranose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C3 atom and a hydroxyl group on the C4 atom by an isopropyldene.
11. The method of claim 5, wherein the unprotected lactone compound is an aldopentose or an aldohexose in a 4-deoxy 1,4 furanose, wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C2 atom and a hydroxyl group on the C3 atom by benzyl, t-butyldimethylsiloxy or triphenyl groups.
12. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 2,5-dideoxy pyranose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C3 atom and a hydroxyl group on the C4 atom by benzyl, t-butyldimethylsiloxy or triphenyl groups.
13. The method of claim 1, further comprising hydrogenating the iminocyclitol to form a hydrogenated iminocyclitol, wherein a stereochemical configuration of the hydrogenated iminocyclitol is the same as the stereochemical configuration of the iminocyclitol.
14. The method of claim 13, wherein hydrogenating the iminocyclitol is carried out in the presence of a catalyst.
15. The method of claim 14, wherein the catalyst comprises PdC and acetic acid.
16. The method of claim 13, further comprising aminating the hydrogenated iminocyclitol to form a N-alkyl-C-alkyl iminocyclitol, wherein a stereochemical configuration of the N-alkyl-C-alkyl iminocyclitol is the same as the stereochemical configuration of the hydrogenated iminocyclitol.
17. The method of claim 16, wherein aminating the hydrogenated iminocyclitol comprises reacting the hydrogenated iminocyclitol with an aldehyde R2CHO and the N atom of the N-alkyl-C-alkyl has a substituent group R2CH2, and wherein R2 is hydrogen or an alkyl group comprising from 1 to 20 carbon atoms, and deprotecting C2 and C3 hydroxyl groups of the N-alkyl-C-alkyl iminocyclitol.
18. The method of claim 16, wherein hydrogenating the iminocyclitol, reacting the hydrogenated iminocyclitol with an aldehyde and deprotecting C2 and C3 hydroxyl groups of the N-alkyl-C-alkyl iminocyclitol are carried out simultaneously.
19. A stereochemically defined iminocyclitol compound or a salt thereof, wherein said compound having a formula selected from the group consisting of
R1 is an alkyl group comprising from 1 to 20 carbon atoms,
R2 is hydrogen or an alkyl group comprising from 1 to 20 carbon atoms,
R3 is hydrogen or an alkyl group comprising from 1 to 20 carbon atoms,
R4 is hydrogen or a first protecting group,
R5 is hydrogen or a second protecting group,
R6 is hydrogen or a third protecting group selected from the group consisting of methanesulfonate, tosylate and triflate;
R7 is hydrogen or a fourth protective group selected from the group consisting of t-butyldimethylsiloxy and tretyl radicals, wherein the first and the second protective form together isopropylidene or cyclohexylidene or are identical protective groups selected from the group consisting of benzyl, t-butyldimethylsiloxy radical and triphenylmethyl.
20. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
and wherein R1, R2 and R6 are as defined in claim 19.
21. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula is
and wherein R1, R2 and R6 are as defined in claim 19.
22. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
23. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
24. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
25. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
26. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
27. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
28. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
29. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2, R6 and R7 are as defined in claim 19 and wherein R4 and R5 form together isopropylidene or are hydrogen atoms.
30. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2, R6 and R7 are as defined in claim 19 and wherein R4 and R5 form together isopropylidene or are hydrogen atoms.
31. An inhibitor of sugar chain related enzymes comprising the compound of claim 19.
32. A medicine comprising the compound of claim 19.
33. The medicine of claim 32, wherein said medicine is an antiviral agent, an anticancer agent or an immunostimulant agent.
34. A method of treating a viral infection comprising contacting a cell infected with a virus causing the infection with the compound of claim 19.
35. The method of claim 34, wherein the virus is a hepatitis virus.
36. The method of claim 35, wherein the hepatitis virus is a hepatitis B virus.
37. The method of claim 35, wherein the hepatitis virus is a hepatitis C virus.
38. The method of claim 35, wherein the virus is a BVDV virus.
39. The method of claim 34, wherein the contacting the cell comprises administering the compound to a subject containing the cell.
40. The method of claim 39; wherein the subject is a mammal.
41. The method of claim 40, wherein the mammal is a human.